Giving it a GO: Giant Roche selects a tiny player at LabCentral for its next cancer R&D partner
Roche has just inked its latest deal in the oncology field. And while the terms may be modest by today’s industry standards, it’s still a major league endorsement for the tiny biotech which scored the connection.
Little GO Therapeutics, which has a staff of 5 working in shared lab space at LabCentral in Cambridge, MA, is getting $9 million upfront for the pact, which spotlights their work on O-linked glycosylation. There’s another $186 million in milestones, completing a package that has been in the works for some time, as GO worked with Roche’s pRED group based in Basel.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.